{"id":360,"title":"The role of microbial enzymes in intervention strategies for metabolic diseases targeting the gut microbiota","title_zh":"微生物酶在靶向肠道菌群的代谢性疾病干预策略中的作用","url":"https://pubmed.ncbi.nlm.nih.gov/42961559","doi":"10.1007/s11427-026-3413-3","pmid":"42961559","journal":"Sci China Life Sci","kind":"paper","lang":"en","published_at":"2026-10-27T00:00:00+00:00","fetched_at":"2026-11-08T03:44:12+00:00","authors":["Gao Y","Gao X","Wang K","Qiao J","Jiang C"],"primary_topic":"repro-microbiome","topics":[{"slug":"repro-endo","score":2.0,"hits":["pcos","polycystic ovary"]},{"slug":"oocyte","score":1.0,"hits":["ovary"]}],"topic_score":2.0,"preference_score":0.0,"preference_labels":[],"llm_score":62.0,"final_score":68.0,"score_dims":{"novelty":55,"rigor":50,"impact":55,"relevance":50,"translation":52},"recommend_reason":"综述覆盖面广，把PCOS纳入肠道菌群-微生物酶框架，对生殖内分泌研究者有参考价值；但以机制叙述为主，无原始数据，生殖特异性证据薄弱，非必读。","keywords":["肠道菌群","微生物酶","短链脂肪酸","多囊卵巢综合征","代谢性疾病","粪菌移植"],"selected":1,"story_id":308,"llm_provider":"deepseek","llm_model":"deepseek-flash","llm_effort":"low","source_key":"pubmed-top-journals","source_name":"PubMed · CNS/大子刊/四大医学刊（生殖相关）","source_tier":1,"mention_count":1,"has_interpretation":false,"journal_key":"sci-china-ls","journal_tier":"general-top","journal_if":8.0,"is_mock":false,"summary_zh":"本文为综述，作者系统梳理肠道菌群及其代谢物在代谢性疾病（肥胖、MASLD、2型糖尿病、动脉粥样硬化及多囊卵巢综合征）中的治疗潜力，重点聚焦微生物酶的作用：将膳食纤维降解为单糖与寡糖并最终生成短链脂肪酸，同时把植物化学物转化为可吸收的活性小分子。作者还总结了靶向胆汁酸代谢、三甲胺生成等微生物通路的小分子激动剂与抑制剂，以及工程菌和粪菌移植等策略，认为微生物酶是上述干预手段的共同基础，并主张以此推进代谢性疾病的酶靶向管理。原文为叙述性综述，未提供原始数据。","summary":"Metabolic diseases-including obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes mellitus (T2DM), atherosclerosis (AS), and polycystic ovary syndrome (PCOS)-pose a significant global health crisis due to their rapidly increasing prevalence. The therapeutic potential of the gut microbiota and its metabolites is gaining recognition, with microbial enzymes playing a pivotal role. These enzymes catabolize dietary fibers into mono- and oligo-saccharides, ultimately yielding beneficial short-chain fatty acids, while concurrently converting phytochemicals into absorbable, bioactive small molecules. An increasing array of small-molecule agonists and inhibitors has been developed to target microbial pathways, such as bile acid metabolism and trimethylamine formation. Furthermore, engineered bacteria and fecal microbiota transplantation are gaining traction as promising therapeutic strategies. This review synthesizes evidence on how microbial enzymes underpin these diverse interventions, aiming to advance the development of microbial enzyme-based management strategies for metabolic diseases.","interpretation_basis":null,"fulltext_status":null,"interpretation":null,"fulltext":{"available":false,"status":null,"reason":"尚未抓取全文（未入选、分数未达阈值，或还没跑 fulltext 步骤）","pmcid":null,"license":null,"chars":0,"source":null,"fetched_at":null}}